Hemophilia A and B Recombinant Factor Replacement Therapy Market, Global Outlook and Forecast 2023-2029

Report ID: MMG251329 | Category: Medical Care | Pages: 69 | Format: PDF | Published Date: October 26,2023

Request Sample Enquiry before buying Ask For Discount

Single User-$3250.00 Multi User-$4225.00

Report Description
View Table of Contents

Report Summary

Haemophilia is a group of inherited genetic disorders which causes abnormal or exaggerated bleeding. It impairs the normal mechanism of blood clotting after an injury. Internal bleeding inside the joint or inside brain is commonly seen in the patients with severe to moderate haemophilia. Its symptoms include bleeding from any site of the body. Internal bleeding is fatal as internal bleeding inside the joint causes joint damage and inside the brain, causes brain damage and seizers. The disease is inherited in an X-linked recessive genetic pattern, therefore males are commonly affected with haemophilia while females are usually carriers of the disease. Haemophilia A is caused by the deficiency of clotting Factor VIII, whereas haemophilia B is caused by the deficiency of Factor IX. It is also known as Christmas disease. The disease management includes factor replacement therapy. Factor replacement therapy is the infusion of factor VIII and IX concentrates through injection to control bleeding. These factor concentrates come from two sources i.e. from human plasma or from genetically engineered cell line made by recombinant DNA technology.
This report aims to provide a comprehensive presentation of the global market for Hemophilia A and B Recombinant Factor Replacement Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hemophilia A and B Recombinant Factor Replacement Therapy. This report contains market size and forecasts of Hemophilia A and B Recombinant Factor Replacement Therapy in global, including the following market information:
Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Hemophilia A and B Recombinant Factor Replacement Therapy market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Haemophilia A Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Hemophilia A and B Recombinant Factor Replacement Therapy include Pfizer, Novo Nordisk, Baxalta, Bayer, Biogen, CSL Behring, Emergent Biosolutions, Spark therapeutics and Uniqure, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Hemophilia A and B Recombinant Factor Replacement Therapy companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Hemophilia A and B Recombinant Factor Replacement Therapy Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Segment Percentages, by Type, 2022 (%)
    Haemophilia A
    Haemophilia B
Global Hemophilia A and B Recombinant Factor Replacement Therapy Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Segment Percentages, by Application, 2022 (%)
    Hospitals
    Clinics
    Ambulatory Surgical Centers
Global Hemophilia A and B Recombinant Factor Replacement Therapy Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Segment Percentages, By Region and Country, 2022 (%)
    North America
        US
        Canada
        Mexico
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
        Nordic Countries
        Benelux
        Rest of Europe
    Asia
        China
        Japan
        South Korea
        Southeast Asia
        India
        Rest of Asia
    South America
        Brazil
        Argentina
        Rest of South America
    Middle East & Africa
        Turkey
        Israel
        Saudi Arabia
        UAE
        Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Hemophilia A and B Recombinant Factor Replacement Therapy revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Hemophilia A and B Recombinant Factor Replacement Therapy revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
    Pfizer
    Novo Nordisk
    Baxalta
    Bayer
    Biogen
    CSL Behring
    Emergent Biosolutions
    Spark therapeutics
    Uniqure
Outline of Major Chapters:
Chapter 1: Introduces the definition of Hemophilia A and B Recombinant Factor Replacement Therapy, market overview.
Chapter 2: Global Hemophilia A and B Recombinant Factor Replacement Therapy market size in revenue.
Chapter 3: Detailed analysis of Hemophilia A and B Recombinant Factor Replacement Therapy company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Hemophilia A and B Recombinant Factor Replacement Therapy in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.

1 Introduction to Research & Analysis Reports
    1.1 Hemophilia A and B Recombinant Factor Replacement Therapy Market Definition
    1.2 Market Segments
        1.2.1 Market by Type
        1.2.2 Market by Application
    1.3 Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Overview
    1.4 Features & Benefits of This Report
    1.5 Methodology & Sources of Information
        1.5.1 Research Methodology
        1.5.2 Research Process
        1.5.3 Base Year
        1.5.4 Report Assumptions & Caveats
2 Global Hemophilia A and B Recombinant Factor Replacement Therapy Overall Market Size
    2.1 Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Size: 2022 VS 2029
    2.2 Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, Prospects & Forecasts: 2018-2029
    2.3 Key Market Trends, Opportunity, Drivers and Restraints
        2.3.1 Market Opportunities & Trends
        2.3.2 Market Drivers
        2.3.3 Market Restraints
3 Company Landscape
    3.1 Top Hemophilia A and B Recombinant Factor Replacement Therapy Players in Global Market
    3.2 Top Global Hemophilia A and B Recombinant Factor Replacement Therapy Companies Ranked by Revenue
    3.3 Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue by Companies
    3.4 Top 3 and Top 5 Hemophilia A and B Recombinant Factor Replacement Therapy Companies in Global Market, by Revenue in 2022
    3.5 Global Companies Hemophilia A and B Recombinant Factor Replacement Therapy Product Type
    3.6 Tier 1, Tier 2 and Tier 3 Hemophilia A and B Recombinant Factor Replacement Therapy Players in Global Market
        3.6.1 List of Global Tier 1 Hemophilia A and B Recombinant Factor Replacement Therapy Companies
        3.6.2 List of Global Tier 2 and Tier 3 Hemophilia A and B Recombinant Factor Replacement Therapy Companies
4 Market Sights by Product
    4.1 Overview
        4.1.1 By Type - Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Size Markets, 2022 & 2029
        4.1.2 Haemophilia A
        4.1.3 Haemophilia B
    4.2 By Type - Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue & Forecasts
        4.2.1 By Type - Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, 2018-2023
        4.2.2 By Type - Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, 2024-2029
        4.2.3 By Type - Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Market Share, 2018-2029
5 Sights by Application
    5.1 Overview
        5.1.1 By Application - Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2022 & 2029
        5.1.2 Hospitals
        5.1.3 Clinics
        5.1.4 Ambulatory Surgical Centers
    5.2 By Application - Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue & Forecasts
        5.2.1 By Application - Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, 2018-2023
        5.2.2 By Application - Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, 2024-2029
        5.2.3 By Application - Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Market Share, 2018-2029
6 Sights by Region
    6.1 By Region - Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2022 & 2029
    6.2 By Region - Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue & Forecasts
        6.2.1 By Region - Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, 2018-2023
        6.2.2 By Region - Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, 2024-2029
        6.2.3 By Region - Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Market Share, 2018-2029
    6.3 North America
        6.3.1 By Country - North America Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, 2018-2029
        6.3.2 US Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2018-2029
        6.3.3 Canada Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2018-2029
        6.3.4 Mexico Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2018-2029
    6.4 Europe
        6.4.1 By Country - Europe Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, 2018-2029
        6.4.2 Germany Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2018-2029
        6.4.3 France Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2018-2029
        6.4.4 U.K. Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2018-2029
        6.4.5 Italy Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2018-2029
        6.4.6 Russia Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2018-2029
        6.4.7 Nordic Countries Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2018-2029
        6.4.8 Benelux Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2018-2029
    6.5 Asia
        6.5.1 By Region - Asia Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, 2018-2029
        6.5.2 China Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2018-2029
        6.5.3 Japan Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2018-2029
        6.5.4 South Korea Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2018-2029
        6.5.5 Southeast Asia Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2018-2029
        6.5.6 India Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2018-2029
    6.6 South America
        6.6.1 By Country - South America Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, 2018-2029
        6.6.2 Brazil Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2018-2029
        6.6.3 Argentina Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2018-2029
    6.7 Middle East & Africa
        6.7.1 By Country - Middle East & Africa Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, 2018-2029
        6.7.2 Turkey Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2018-2029
        6.7.3 Israel Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2018-2029
        6.7.4 Saudi Arabia Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2018-2029
        6.7.5 UAE Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2018-2029
7 Hemophilia A and B Recombinant Factor Replacement Therapy Companies Profiles
    7.1 Pfizer
        7.1.1 Pfizer Company Summary
        7.1.2 Pfizer Business Overview
        7.1.3 Pfizer Hemophilia A and B Recombinant Factor Replacement Therapy Major Product Offerings
        7.1.4 Pfizer Hemophilia A and B Recombinant Factor Replacement Therapy Revenue in Global Market (2018-2023)
        7.1.5 Pfizer Key News & Latest Developments
    7.2 Novo Nordisk
        7.2.1 Novo Nordisk Company Summary
        7.2.2 Novo Nordisk Business Overview
        7.2.3 Novo Nordisk Hemophilia A and B Recombinant Factor Replacement Therapy Major Product Offerings
        7.2.4 Novo Nordisk Hemophilia A and B Recombinant Factor Replacement Therapy Revenue in Global Market (2018-2023)
        7.2.5 Novo Nordisk Key News & Latest Developments
    7.3 Baxalta
        7.3.1 Baxalta Company Summary
        7.3.2 Baxalta Business Overview
        7.3.3 Baxalta Hemophilia A and B Recombinant Factor Replacement Therapy Major Product Offerings
        7.3.4 Baxalta Hemophilia A and B Recombinant Factor Replacement Therapy Revenue in Global Market (2018-2023)
        7.3.5 Baxalta Key News & Latest Developments
    7.4 Bayer
        7.4.1 Bayer Company Summary
        7.4.2 Bayer Business Overview
        7.4.3 Bayer Hemophilia A and B Recombinant Factor Replacement Therapy Major Product Offerings
        7.4.4 Bayer Hemophilia A and B Recombinant Factor Replacement Therapy Revenue in Global Market (2018-2023)
        7.4.5 Bayer Key News & Latest Developments
    7.5 Biogen
        7.5.1 Biogen Company Summary
        7.5.2 Biogen Business Overview
        7.5.3 Biogen Hemophilia A and B Recombinant Factor Replacement Therapy Major Product Offerings
        7.5.4 Biogen Hemophilia A and B Recombinant Factor Replacement Therapy Revenue in Global Market (2018-2023)
        7.5.5 Biogen Key News & Latest Developments
    7.6 CSL Behring
        7.6.1 CSL Behring Company Summary
        7.6.2 CSL Behring Business Overview
        7.6.3 CSL Behring Hemophilia A and B Recombinant Factor Replacement Therapy Major Product Offerings
        7.6.4 CSL Behring Hemophilia A and B Recombinant Factor Replacement Therapy Revenue in Global Market (2018-2023)
        7.6.5 CSL Behring Key News & Latest Developments
    7.7 Emergent Biosolutions
        7.7.1 Emergent Biosolutions Company Summary
        7.7.2 Emergent Biosolutions Business Overview
        7.7.3 Emergent Biosolutions Hemophilia A and B Recombinant Factor Replacement Therapy Major Product Offerings
        7.7.4 Emergent Biosolutions Hemophilia A and B Recombinant Factor Replacement Therapy Revenue in Global Market (2018-2023)
        7.7.5 Emergent Biosolutions Key News & Latest Developments
    7.8 Spark therapeutics
        7.8.1 Spark therapeutics Company Summary
        7.8.2 Spark therapeutics Business Overview
        7.8.3 Spark therapeutics Hemophilia A and B Recombinant Factor Replacement Therapy Major Product Offerings
        7.8.4 Spark therapeutics Hemophilia A and B Recombinant Factor Replacement Therapy Revenue in Global Market (2018-2023)
        7.8.5 Spark therapeutics Key News & Latest Developments
    7.9 Uniqure
        7.9.1 Uniqure Company Summary
        7.9.2 Uniqure Business Overview
        7.9.3 Uniqure Hemophilia A and B Recombinant Factor Replacement Therapy Major Product Offerings
        7.9.4 Uniqure Hemophilia A and B Recombinant Factor Replacement Therapy Revenue in Global Market (2018-2023)
        7.9.5 Uniqure Key News & Latest Developments
8 Conclusion
9 Appendix
    9.1 Note
    9.2 Examples of Clients
    9.3 Disclaimer

FAQ's

What does the report cover (Scope)?

It contains all the geographic trends, and market analysis for global market

ENTER REPORT NAME TO SEARCH

Hemophilia A and B Recombinant Factor Replacement Therapy Market, Global Outlook and Forecast 2023-2029

Report Summary

Table of Contents

FAQ's

What does the report cover (Scope)?